Home » Posts tagged with » Switzerland (Page 2)
Orphan Technologies begins OT-58 phase 1/2 trial in classical homocystinuria

OT-58 clinical trial news : Swiss pharma company Orphan Technologies has dosed the first patients in a phase 1/2 trial, called CBS-HCY-01, of its modified recombinant enzyme therapy OT-58 in classical homocystinuria. OT-58 has been designed to dramatically reduce tissue and plasma levels of homocysteine, thereby potentially preventing, delaying, and reversing clinical abnormalities, and lifting […]

Continue reading …
Novartis to acquire US biopharma company Endocyte for $2.1bn

Swiss pharma giant Novartis has signed a deal valued at about $2.1 billion to acquire US biopharma company Endocyte in a move to expand its expertise in radiopharmaceuticals for the treatment of cancer. According to the merger terms, the Swiss pharma giant will buy all the shares of Endocyte at $24 per share. The US […]

Continue reading …
Roivant launches Respivant Sciences to develop drugs for respiratory diseases

Roivant Sciences has launched a new biopharma company named Respivant Sciences which will focus on developing innovative therapeutics for serious respiratory diseases. The new biopharma company of Roivant Sciences will be headed by Bill Gerhart – CEO, Ahmet Tutuncu – Executive Vice President for Clinical and Regulatory, and Pravin Soni – Executive Vice President for […]

Continue reading …
Urovant licenses overactive bladder gene therapy hMaxi-K from Ion Channel

Urovant Sciences has acquired global licensing rights for the development and commercialization of a gene therapy called hMaxi-K from Ion Channel Innovations, which is being developed for the treatment of overactive bladder (OAB) in patients who did not respond to oral pharmacologic therapy. As of now, there are no treatments for overactive bladder that have […]

Continue reading …
Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients

Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]

Continue reading …
Novartis to in-license atopic dermatitis drug MOR106 from MorphoSys, Galapagos

Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that could go up to $1.1 billion. The Swiss drugmaker will make an upfront payment of €95 million ($111 million) to Galapagos and MorphoSys apart from potential milestone payments of up […]

Continue reading …
Page 2 of 212